PubMed Health⌕ Search

Biomedical subjects

P P García-Luna

Publications and source records attributed to P P García-Luna.

At least 19 recordsLinked to original sources
PubMed2006

[Causes and impact of hyponutrition and cachexia in the oncologic patient].

The maximal expression of hyponutrition in cancer is tumoral cachexia, which will direct or indirectly account for mortality in one third of cancer patients. Causes of hyponutrition in cancer are related with the tumor, the patient, or therapies, and summarily we may differentiate four main mechanisms by which hyponutrition may occur in cancer patients: Poor energy and nutrients intake; Impairments of nutrient digestion and/or absorption; Increased demands; Impairments of nutrient metabolism; Any modality of oncologic therapy induces hyponutrition occurrence, especially in those cases in which several therapies are administered to cure cancer (surgery, radiotherapy, chemotherapy). Hyponutrition in cancer patients produces a decrease in muscle mass, which leads to strength loss, having important consequences on functional status of the individual since it increases dependence on others (relatives, caregivers) and decreases quality of life. Besides, hyponutrition is associated to poorer response to radiotherapy and chemotherapy, or poorer tolerability of such therapies. Hyponutrition also impairs scarring mechanisms and increases the risk for surgical complications such as suture dehiscence or infections. Both infectious complications and surgically derived complications entail longer hospital staying, which contributes to increase management costs. Finally, effects of hyponutrition on mortality should not be neglected, with severe weight loss being associated to lower survival.

Cachexia↗
PubMed2005

[Percutaneous endoscopic gastrostomy. Reality in the intra- and extra-community clinical nutritional practice].

BACKGROUND: This study aimed to review our experience during 8 years in the use of percutaneous endoscopic gastrostomy (PEG) and its application in home enteral nutrition (HEN). MATERIAL: We studied 207 patients (56 women and 151 men) who had undergone a PEG from the beginning of 1994 to the end of 2002 as they needed prolonged enteral nutrition (> 4 weeks). In those cases in which home enteral nutrition was programmed, the patients/relatives were trained in the techniques and care of the PEG and EN, and the control was done through the nutrition out-patient clinic. RESULTS: Mean duration time of the PEG was 640 days and 175 patients (84.6%) needed PEG for more than 60 days and 135 for more than 6 months. Mean calorie supply was 1,730 +/- 288 Kcal/day. Administration mode was by intermittent infusion due to seriousness in 162 cases and continuous infusion through volemetric pump in 45 patients. In 2 patients with hyperemesis gravidarum, percutaneous endoscopic gastrojejunostomy (PEGJ) was done in the 3rd and 4th month of pregnancy, the pregnancy finishing successfully by vaginal delivery. Performance of PEG facilitated hospital discharge and programming of home enteral nutrition in 195 patients (94%). The most frequent complications were gastrostomy infection that occurred in 41 patients and the appearance of granuloma in the ostomy in 34 cases. Only one patient died in direct relationship due to peritonitis after PEG. CONCLUSION: Our study includes the advantages of PEG as an enteral nutrition technique, permitting the establishment of a home enteral nutrition program with limited incidence of complications and very low mortality.

Enteral Nutrition↗
PubMed2001

[Subclinical thyroid disease in institutionalised healthy geriatric population].

BACKGROUND: Our aim was to determine the prevalence of subclinical thyroid disease in a healthy institutionalised geriatric population. PATIENTS AND METHOD: We determined TSH, free T4 and antithyroid antibodies from 242 healthy elderly subjects living in Andalusian public nursing homes. RESULTS: Subclinical hypothyroidism was detected in 3.71% of cases; clinical hypothyroidism in 1.65%; subclinical hyperthyroidism in 0.82%,and autoimmune disease in 10.33%. CONCLUSIONS: There is a high rate of clinically undetected thyroid dysfunction among the healthy institutionalised geriatric population. Therefore, a hormonal screening may be justified in this population.

Aged↗
PubMed2001

Effects of minor constituents (non-glyceride compounds) of virgin olive oil on plasma lipid concentrations in male Wistar rats.

We aimed to assess the effects of minor constituents (MC) from virgin olive oil upon the plasma lipid profile of experimental animals. Therefore, 32 Wistar rats were fed for 6 weeks with one of four different diets with a similar fatty acid composition but different MC: high-oleic sunflower oil (HOSO), virgin olive oil (VOO), 400%-MC enriched olive oil (EOO) and MC poor (impoverished) olive oil (IOO). At the end of the week 6 of dietary treatment, blood samples were obtained for analysis of lipid composition. A statistically significant influence was observed upon both total HDL (1.593+/-0.4, 1.204+/-0.212, 0.991+/-0.244 and 0.827+/-0.279 mmol/L for EOO, HOSO, VOO and IOO, respectively, Kruskal-Wallis test, P<0.05) and HDL(2)cholesterol levels (1.16+/-0.26, 0.576+/-0.191, 0.585+/-0.216 and 0.583+/-0.207 mmol/L for EOO, HOSO, VOO and IOO, respectively, Kruskal-Wallis test, P<0.05). No statistically significant effect was observed upon LDL-cholesterol or triglycerides. Thus, MC supplementation has beneficial effects on HDL concentrations in Wistar rats.

Animals↗
PubMed2001

Nutritional support in chronic renal failure: systematic review.

BACKGROUND AND AIMS: The purpose of this systematic review was to locate and assess in patients with chronic renal disease the quality of scientific evidence to establish graded recommendations based on the efficacy and effectiveness of nutritional support. METHODS: Computerized and online versions of MEDLINE (from 1989 through March 1999) and EMBASE (from 1988 through January 1999) were consulted. The Cochrane Library and the online Healthstar (from 1975) databases were also searched for clinical trials. A total of 593 studies were assessed. Following methodological review (primary reviewer), only 45 studies reviewed met criteria for selection and were analyzed by a group of experts (secondary reviewer). A final consensus was reached between the co-ordinators, experts and methodologists. RESULTS AND CONCLUSIONS: Low and very low-protein diets associated with specific enteral supplements are indicated in most patients with chronic renal disease and in patients with incipient diabetic nephropathy to slow progression of disease and to improve their overall status, contributing to improved survival (grade A recommendation). The use of protein-restricted diets in diabetic nephropathy is only indicated in type I diabetes mellitus (grade A recommendation). An improvement in nutritional parameters was found when specific diets were given in chronic renal disease (grade C recommendation).

Chronic Disease↗
PubMed2000

[Oral nutritional supplements. Are they useful?].

Oral nutritional supplements are products included in enteral nutrition, preferably used in hospital settings, although their use in the community is gradually increasing and in the United Kingdom has doubled in the last seven years, with prescriptions covering a wide range of the population from children to the elderly, and different pathologies affecting their nutritional status. There is, however, no consensus on the usefulness of oral nutritional supplements among these patients, so we do not have any recommendations for use. In this paper we have reviewed the various studies available in the literature in order to clarify the usefulness of these supplements in different contexts or pathologies.

Acquired Immunodeficiency Syndrome↗
PubMed1999

[Update of enteral nutrition at the patient's home].

Home enteral nutrition is the administration of enteral formulae into the digestive tract using a tube, with the objective of preventing or correcting malnutrition patients who are seen at home. Home enteral nutrition is a type of nutritional support that is growing, that improves the nutritional status of the patient with a lower cost and with a greater quality of life of the family unit than enteral nutrition in the hospital. The prevalence is clearly increasing although the data of the national registers of patients with at home enteral nutrition are under estimated. Patients who are candidates for home enteral nutrition can be all those with an indication for enteral nutrition and whose underlying disease is stabilized or does not require all the technical means of the hospital in a permanent and essential manner. Neoplasias and neurological diseases are those that benefit most from at home enteral nutrition and in all registries each group varies between 30 and 40%. All access routes and all enteral nutrition formulae can be used in patients with home enteral nutrition. The use of percutaneous endoscopic gastrostomies is ever more recommended in patients who need at home enteral nutrition for a period longer than 4 weeks. Since the publication of the Ministerial Order of June 2nd 1998, home enteral nutrition is considered a health care service that can be covered by the Social Security. This order lists a series of disease that are likely to be treated with at home enteral nutrition (in our opinion the list is not complete but it is likely to be changed in the future by an Assessing Committee), and it presents some basic norms that all patients must comply with, regardless of the autonomous community in which they live. Before beginning at home enteral nutrition the training of the patient and/or the family with regard to the management of at home enteral nutrition is essential. The existence of qualified personnel with experience in this nutritional support technique, as well as the collaboration between Primary Care and Specialized Care (Clinical Nutrition Units if these exist in the health care area) is essential for the control and follow up of the patient with at home enteral nutrition.

Enteral Nutrition↗
PubMed1998

Enteral nutrition by percutaneous endoscopic gastrojejunostomy in severe hyperemesis gravidarum: a report of two cases.

We describe the first two cases in which percutaneous endoscopic gastrojejunostomy was used as a means to provide enteral nutrition in severe hypermesis gravidarum. The use of this method of enteral access provided an alternative to parenteral nutrition, was well tolerated, cost-effective and had no major complications. In both cases the nutritional goal for mothers as well as appropriate fetal growth and development were achieved.

Adult↗
PubMed1998

[Treatment with low-protein diet and caloric supplements in patients with chronic kidney failure in predialysis. Comparative study].

The low-protein diet (LPD) is used in patients with advanced chronic renal failure (CRF) to improve their symptoms and decrease the progression of CRF. LPD entails the risk for caloric malnutrition, which increases protein catabolism. Two groups were obtained from a total of 33 patients with CRF with LPD (0.6 g protein/kg/day): control group (group C), which went on with the same diet, and a group S, in which a portion of proteins and calories were provided through a low-protein and hypercaloric supplement (Suplena). During 6 months the protein intake and the evolution of the nutritional status and renal function were studied and compared between both groups. Additionally, tolerance and secondary effects of the supplement were studied in group S. Twenty-two patients (eleven in each group) completed the six month follow-up. At the end of the study, group S had the nutritional parameters better preserved, came closer to the low-protein diet objective, had a better compliance with therapy and had a less marked decrease in renal function--as measured by creatinine clearance--than group C. Tolerance to supplement was good in more than 70% of patients and secondary effects--nausea, vomiting and loss of appetite--occurred in 18% of patients at the end of the 6 months. We conclude that the use of this supplement in an LPD is usually well tolerated, enhances the compliance with the diet and can be of benefit for the mebacolic-nutritional status.

Dietary Proteins↗
PubMed1997

Esophageal obstruction by solidification of the enteral feed: a complication to be prevented.

We report three cases of esophageal obstruction due to solidification of enteral feed refluxed from the stomach in patients being fed through a nasogastric tube. All three patients were administered sucralfate continuously by tube. The few previous descriptions of this rare complication have also implicated sucralfate with its pathogenesis. Given its clinical importance and the growing use of long-term enteral nutrition, this adverse event needs to be considered.

Adult↗
PubMed1994

[Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].

BACKGROUND: The presentations of intravenous or depot bromocriptine (bromocriptine LA or long acting, Pariodel LA and bromocriptine LAR or long acting repeatable, Pariodel LAR) have improved the efficacy and the tolerance of oral bromocriptine. In contrast to bromocriptine LA, bromocriptine LAR may be repeatedly administered intramuscularly. METHODS: Five patients with macroprolactinoma and 4 with microprolactinoma were included in the study. A 50 mg bottle of bromocriptine LAR was administered intramuscularly every month, over a minimum period of 6 months. PRL was determined prior to the study, 1, 3, 7, 14, and 28 days following the initial dose of bromocriptine and thereafter with monthly periodicity. RESULTS: The PRL values decreased in those patients with macroprolactinomas following the administration of bromocriptine LAR; in 2 patients the monthly doses of bromocriptine LAR was increased to 100 mg since the month after the initial dose PRL remained greater than 200 ng/ml with serum RPL normalizing in most of the patients at 6 months of treatment. In two of the three patients who presented visual changes a clear improvement was observed and in all the cases a reduction in the size of the macroprolactinoma was found upon CAT control at 6 months. The PRL values also decreased in the patients with microprolactinomas following administration of bromocriptine LAR, although the response was not as homogeneous as in the patients with macroprolactinomas due to that at 6 months 2 patients continued to have slightly elevated serum PRL levels. The microadenoma persisted in the control CAT at 6 months except in one case. Local and general tolerance to bromocriptine LAR was very good. CONCLUSIONS: This study indicates good tolerance to bromocriptine LAR, being a therapeutic option in the treatment of macroprolactinomas.

Adult↗